GlassScriptPhysician profile
January J Kim
NPI 1609845759
$3,102.66
in general payments reported to CMS, 2019-2025
23 companies · $736 in 2025
The $736 reported for 2025 was more than what 79% of Psychiatric/Mental Health, Adult (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $174).
See the full distribution for Psychiatric/Mental Health, Adult (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $689 · 2022: $460 · 2023: $754 · 2024: $464 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,953.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $672.43 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $619.70 | 2023-2025 | Spravato |
| Lundbeck LLC | $315.80 | 2021-2025 | Rexulti |
| Alkermes, INC. | $220.20 | 2021-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $178.26 | 2021-2025 | Rexulti, Abilify Maintena |
| Neuronetics, INC. | $124.59 | 2023-2025 | Neurostar Tms Therapy System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.95 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $97.70 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $96.93 | 2022-2025 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $84.07 | 2021-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $76.91 | 2021-2022 | |
| Neos Therapeutics, LP | $69.88 | 2024-2025 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $65.61 | 2021-2022 | |
| Corium, LLC | $64.92 | 2022-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $58.25 | 2023-2024 | Austedo Xr |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $47.31 | 2023-2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $44.52 | 2022 | |
| Axsome Therapeutics, INC. | $43.04 | 2023 | Auvelity |
| Almatica Pharma LLC | $36.09 | 2021-2022 | |
| Biogen, INC. | $22.27 | 2024 | Zurzuvae |
| Adlon Therapeutics L.P. | $21.11 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.55 | 2023 | Quviviq |
| Eisai INC. | $14.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw January Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.